Uy Ear
Stock Analyst at Mizuho
(3.34)
# 870
Out of 4,789 analysts
59
Total ratings
47.06%
Success rate
18.19%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $15.64 | +34.27% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $10.60 | +88.68% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.27 | +270.37% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $33.02 | +21.14% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $7.95 | +101.26% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $13.18 | +203.49% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $63.82 | +180.48% | 5 | May 17, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $16.61 | +26.43% | 10 | May 9, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $12.03 | +91.19% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $110.60 | +26.58% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $165.84 | -75.88% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.39 | +622.02% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.71 | +324.75% | 2 | Mar 1, 2023 |
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $15.64
Upside: +34.27%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $10.60
Upside: +88.68%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.27
Upside: +270.37%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $33.02
Upside: +21.14%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $7.95
Upside: +101.26%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $13.18
Upside: +203.49%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $63.82
Upside: +180.48%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $16.61
Upside: +26.43%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $12.03
Upside: +91.19%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $110.60
Upside: +26.58%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $165.84
Upside: -75.88%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.39
Upside: +622.02%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.71
Upside: +324.75%